Anti-CD47 antibodies suppress tumor growth, enhance antitumoral macrophage recruitment, and activate CD8+ T cells in multiple tumor models, including glioblastoma, where CD47 blockade reprogrammed TAMs (25, 85). The gene discussed is CD47; the disease is glioblastoma.